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Background: The Maedi-Visna (MV) lentivirus causes two slowly progressive eventually fatal diseases of sheep,
Maedi, a progressive interstitial pneumonia, and Visna, a progressive demyelinating disease of the central nervous
system. Other lentiviruses also cause fatal slow infections in their natural hosts, e.g. the HIV virus in humans. Results
of experimental vaccination against any lentivirus where vaccinees are challenged by natural routes, may therefore
be of general interest. From 1991–1998 experiments with formalin-inactivated whole Maedi-Visna virus vaccine
were carried out in the Department of Microbiology at the University of Iceland. Western Blot tests showed good
immune response to all major proteins of the virus. When aluminium hydroxide was added to the vaccine all
vaccinees developed neutralizing antibodies to the vaccine strain at titers 1/8 – 1/256. After housing 5 twin pairs,
one twin in each pair vaccinated, the other unvaccinated, with infected sheep for 4 years, all the unvaccinated
twins became infected, but only 2 of their vaccinated siblings as confirmed by virus cultivation experiments on
tissues from their lungs spleens lymph nodes and choroid plexuses.
Results: One twin in each of 40 female twin pairs, born into a Maedi-Visna-infected sheep flock and kept under
natural farming conditions in Cyprus, was vaccinated at birth, 3 weeks and 3 months, with formalin-inactivated
whole Maedi-Visna lentivirus vaccine adjuvanted with aluminium hydroxide. 17 mothers of the twins were
seronegative, 13 seroconverting and 10 had old infection. Of 17 vaccinees born to seronegative mothers 9 were
uninfected at 28 months, but only 2 of their unvaccinated siblings. Of 13 unvaccinated twins born to
seroconverting mothers, 12 caught infection during their first 10 weeks, but only 4 of their vaccinated siblings.
Vaccination had no effects on 10 vaccinees born to mothers with long-standing Maedi-Visna infections and broad
andibody response at birth of their lambs.
Conclusion: Compared with their unvaccinated siblings, natural infection was delayed in significant number of
vaccinated twins born by seronegative and seroconverting mothers and vaccinated at birth, 3 weeks and 3 months
with formalin inactivated whole MV vaccine adjuvanted with aluminium hydroxide. Maternal antibodies interfered
with vaccination so early in life if the mother had old infection.
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Maedi, progressive interstitial pneumonia, and Visna,
progressive demyelinating disease of the central nervous
system, are two serious, slowly progressive and eventu-
ally fatal diseases of sheep caused by the same lentivirus
infection, the Maedi-Visna (MV) virus infection [1-3].
Other lentiviruses also cause fatal slow infections e.g. the
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inactivated whole Maedi-Visna virus vaccine were
carried out in the Department of Microbiology at the
University of Iceland [4,5]. The vaccinees were kept in
isolation cubicles during the vaccination period. Western
Blot (WB) tests on sera from the first 16 vaccinees
showed good immune response to all major proteins of
the virus, and when aluminium hydroxide was added to
the vaccine they all developed neutralizing antibodies to
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clearer and neutralizing titers rose [4].
Housing infected sheep with healthy flocks was the
main mode of natural Maedi-Visna transmission from
one farm to another in Iceland during the epidemic
1933–1952 [3]. This route of transmission was therefore
chosen as the challenge in these experiments. The 16
fully vaccinated sheep and their controls were moved
from their isolation cubicles to a sheep hut and housed
there with 6 heavily infected sheep. After being housed
with the infected sheep for 4 years, 5 unvaccinated twins
in 5 twin pairs had become infected, but only 2 of their
vaccinated siblings. These results were confirmed by
virus cultivation experiments on tissues from spleens,
lymph nodes, lungs and choroid plexus from all 10 twins
[5]. After these experiments it was tempting to test the
effects of this vaccine in a naturally-infected sheep flock.
Infected flocks are not available in Iceland; the last one
being eradicated by slaughter in 1965. Maedi-Visna in-
fection is common in the Mediterranean region of
Europe. The National Veterinary Services in Cyprus
were introduced to these results, decided to participate
in a field trial of the vaccine and found a place for the
experiment on one very good sheep farm.
Methods
Vaccine strain of virus
Icelandic Maedi-Visna strain K796 was selected for
preparation of vaccine, because long-term animal experi-
ments carried out 1960–1975 had demonstrated that
this strain was highly immunogenic and caused both
Visna and Maedi in the experimental sheep [6]. Strain
K796 was originally isolated from the brain of a symp-
tomatic sheep in the 5th brain-to-brain laboratory pas-
sage of natural Visna. In preparation for this vaccine
trial in Cyprus, WB tests on a few sera from older sheep
in the flock that had been selected to house the experi-
ment tested positive against strain K796, indicating that
related strains circulated in the flock.
Vaccine preparation
Virus was grown in sheep choroid plexus tissue culture
from 4 month-old Icelandic lambs. Cells were grown in
tissue-culture flasks on a flat surface, (80cm2), in
medium 199 with Earl’s salts (199E, Gibco, UK) and 20%
Icelandic lamb serum. When the cell cultures were con-
fluent the medium was changed to 199E with 2% lamb
serum and the tissue cultures infected. Cytopathic
lesions were at their maximum, 8–9 days after infection
and then the tissue culture fluid was harvested, cell deb-
ris removed by centrifugation at 3332G for 40 minutes
and the supernatant inactivated in formalin (Merk,
Germany) 1:4000 at 37°C for 4–5 days. At the end of the
inactivation period the fluid was divided into 200 mlaliquots, which were centrifuged at 22524G for 4 hrs.
All supernatant fluid was then discarded and the pellet
in each bottle resuspended in 2 ml. medium 199E with-
out serum, thus concentrating the virus preparation
100x. In order to test for failure of inactivation, 2 ml. of
concentrate from one pellet were inoculated into 2 bot-
tles of tissue culture and incubated 5–6 weeks with fre-
quent microscopic examinations for cytopathic lesions.
When this control was finished, sterile aluminium hy-
droxide (Fisher Scientific Company, USA. E&A Tested
Purity Reagent) powder, 5 mg/ml, was added to the vac-
cine. After mild shaking twice a day for one week the
vaccine was ready for use.
Vaccinees
The vaccinees were one twin lamb in each of 40 female
twin pairs born to mothers of the Chios breed of sheep
into an infected flock of about 700 adult sheep on one
well maintained sheep farm in Cyprus. The other twin
served as an unvaccinated control throughout the ex-
periment. Mothers of these twins were selected accord-
ing to results of AGID screening tests on all pregnant
ewes in the flock a month before birth of these lambs:
30 mothers seronegative and, for comparison, 10
mothers seropositive in the AGID test. Blood samples
were collected from mothers and both twins at birth of
each twin pair when one twin in each pair was vacci-
nated. Blood samples from both twins in each pair were
also collected 3 weeks after the first, second and third
vaccination, then again 6 weeks after the 3rd vaccination
and thereafter at 5–7 months intervals during the next 2
years. Serum was harvested from all blood samples and
frozen at – 20°C. The original plan for this experiment
was to vaccinate one twin lamb in 30 female twin pairs
born into a naturally infected sheep flock by seronega-
tive mothers and, for comparison, one twin in 10 pairs
born by seropositive mothers. When sera were recol-
lected from the mothers at birth of their lambs, 13 of
the 30 mothers negative in AGID tests 4–5 weeks earlier
were positive in WB tests against the vaccine strain
K796. All the 10 mothers previously positive in the
AGID tests were positive in the WB tests. In accordance
with different immunological experience of the mothers
the vaccinees were divided into 3 groups:
Group 1) 17 twin pairs born by mothers seronegative
both in AGID and WB tests.
Group 2) 13 twin pairs born by mothers negative in
AGID, but positive in WB tests.
Group 3) 10 twin pairs born by mothers positive both
in AGID and WB tests.
The flock was kept and fed on the sheep farm under
natural farming conditions throughout the experiment.
Table 1 Comparison of CF titers against 3 Maedi-Visna
strains, vaccine strain K796 and 2 local strains 10B and
7W from 2 sheep of the flock in Cyprus
Titer of serum from one sheep
infected intrapulmonarily with
300.000 TCID 50 of virus K796
Virus strains
K796 10B 7W
Serum 13 months after infection with K796 128 16 8
Serum 3 years after infection with K796 256 32 16
Titer of serum from one naturally
infected sheep in Cyprus
16 128 128
* In these CF tests serial 2 fold dilutions of sera ranging from dilutions 1/4 - 1/
512 were tested against the 3 strains. Four-fold or larger difference in titer is
significant.
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kept with their mothers for their first 35 days of life,
then taken away from the mothers and moved to the
main flock. This applied to the experimental lambs as
well as all other lambs born into this flock.
This experiment was approved of the Chief Veterinary
Officer in Cyprus, who also was the Director of the
Department of Veterinary Services at the Ministry of
Agriculture, Natural Resources and Environment. The
Ministry supported this work by a grant for maintenance
of the experimental sheep, as two branches of the Na-
tional Veterinary Services, the Central Virus Laboratory
in Nicosia and the National Veterinary Services in Lim-
assol, were major participants in this work.
Vaccination
Vaccine, 1 ml per dose, was given at the birth of the vac-
cinee, a second injection 3 weeks later, then a third in-
jection when the lambs were 3 months old. There were
no later boosters. Vaccine was injected intramuscularly
with no side effects.
Diagnostic laboratory work
The AGID screening tests, then used for diagnostic work
at the Virus Laboratory of the National Veterinary
Services in Cyprus were performed on over 600 pregnant
ewes on the farm during the last month of their pregnancy
in order to select mothers for the vaccinees. Commercially
available test plates (Weybridge Laboratories, England)
were used in this work and the tests were performed by
senior technicians according to instructions for use of the
plates. Methods for Western Blots (WB) and Complement
Fixation (CF) tests done in Iceland have been previously
described and compared [7,8]. The CF test was chosen for
laboratory diagnosis of infection in vaccinees and their un-
vaccinated siblings because it is a reliable diagnostic test
[3,6,9]. It is comparable with the WB test in time of anti-
body response after infection [8]. Good CF antigens, that
is high titer untreated tissue culture fluid, could be pre-
pared from local Maedi-Visna strains isolated from other
sheep in the flock. Their primary isolation in choroid
plexus cells from Icelandic lambs was time consuming
and their growth low and slow as compared with K796.
Serial 2 fold dilutions of sera were prepared and mixed
with antigen and 4 units of complement (Guinea Pig
Complement, Harlan Sera Lab, UK). This mixture was
kept overnight at + 4°C, the hemolytic system added next
morning and reading done 3–4 hours later. Four-fold or
larger difference in titer is significant in a CF test [9].
Results
Immunity in the sheep flock
About 40% of the 600 pregnant ewes tested in AGID
tests were positive. Later in this study we found that 13of the 30 mothers negative in the AGID test were posi-
tive in Western Blot (WB) tests against the vaccine
strain of virus. All the 10 mothers previously positive in
the AGID test, also tested positive in the WB test. If
these results of the WB tests hold for the whole flock, it
is heavily contaminated with Maedi-Visna virus infec-
tion. No illness was found in the flock during the time
of this trial and the sheep thrived well.
Strain difference
Local strains used as CF antigens showed 8-16-fold
higher titers than K796 in sera from the infected sheep.
Table 1 shows comparison of CF titers against three CF
antigens, two from local strains and the vaccine strain
K796.
Results of vaccination
The results of the vaccination varied according to the
immune status of the mothers at birth of their twins.
Therefore, the twin pairs were divided into 3 groups as
previously described. Table 2 shows the results of the
vaccination in all 3 groups.
Table 2 shows that during the first half of their first
year there was no seroconvertion detectable in any lamb
in Group 1. At 11 months 3 lambs had seroconverted, 2
unvaccinated and 1 vaccinee. At 16 months of age, 15
lambs had caught infection: 9 unvaccinated and 6 vacci-
nees. At the end of the second year, 14 of 17 unvaccin-
ated lambs had seroconverted but only 8 vaccinees. At
28 months 9 vaccinees were still seronegative, but only 2
of their unvaccinated siblings. The difference is signifi-
cant (P = 0.025; Fisher’s Exact Test).
Table 2 also shows that during their first 2 months of
life 12 of the 13 unvaccinated twins in Group 2 became
infected and seroconverted, but only 4 of their vacci-
nated siblings, and the 5th one at 5 months of age. This
difference at five months is significant (P = 0.01; Fisher’s
Exact Test). Late in their first year of life, 6 of the vacci-
nated twins seroconverted and the last 2 early in their
second year. At 16 months of age, all 26 lambs in this
group were infected. When the vaccinees are compared
Table 2 Number of infected lambs in the 3 groups
Age in months: 2-4 5 11 16 23 28
Group 1
Vaccinated 0 0 1 6 8 8 (47%)
Unvaccinated 0 0 2 9 14 15 (88%)
Group 2
Vaccinated 4 5 11 13 13 13
Unvaccinated 12 12 12 13 13 13
Group 3
Vaccinated 0 0 0 At 18 months 9 pairs alive.
Unvaccinated 0 0 0 In 4 pairs both lambs seronegative.
In 3 pairs both lambs infected.
In 2 pairs one lamb negative one
vaccinee and one unvaccinated.
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ling milk from the same mother their first 35 days, vac-
cination is the most likely reason for the delay of milk
born infection in the vaccinated twins.
Vaccination of the 10 twins in Group 3 was unsuccess-
ful. There was no infection detected in any twin in this
group during their first year of life, in contrast with the
experience in Group 2. Of 9 twin pairs in Group 3, alive
at 18 months after their first vaccination, both lambs in
4 pairs were seronegative, both lambs in 3 pairs sero-
positive and one lamb seropositive in 2 pairs, a vaccinee
in one pair, and unvaccinated lamb in the other. It is
probably not possible to vaccinate newborn or very
young lambs if they are loaded with maternal antibodies
following long-standing infection of the mother.
Discussion
Adverse reactions
The vaccine was well tolerated, and there were no ad-
verse reactions, neither swelling after the injections nor
systemic reactions. During the earlier experiments with
this vaccine in Iceland the experience was the same [4].
Antibody response
The antibody response to this vaccine was previously
studied in seronegative Icelandic sheep kept in isolation,
in spite of the fact that Iceland has been free of Maedi-
Visna infection since 1965 [4]. In this field trial we did
not test for antibody response after vaccination, because
the vaccinees were exposed to natural infection from
their environment every day after their birth, and there-
fore it was impossible to be certain whether they were
responding to the vaccination or early natural infection
from their environment. For the immune response to
the vaccine we therefore refer to the studies done in iso-
lation of the 16 seronegative Icelandic vaccinees, men-
tioned here in the Background section [4].Protection
As mentioned here in the Background section, a small
experiment on 5 twin-pairs, one twin in each pair vacci-
nated and the other an unvaccinated control, showed,
that after 4 years of close contact with sheep infected
with the vaccine strain of virus all the unvaccinated
twins had seroconverted, but only 2 of their vaccinated
siblings. Cultivation of virus from lungs, spleens, hilus
lymph nodes and choroid plexuses from all 10 twins
confirmed these results. The 3 seronegative twins tested
were also negative in all the tissue culture experiments
[5]. This type of work can only be done at laboratory
conditions, not at the natural conditions on an infected
farm. In slow infections were you count the incubation
period in years without clinical signs, you have to select
the indirect method of antibody response as the most re-
liable method to separate real infection from contamin-
ation of specimens taken at field work. In this field trial
the results shown in Table 2 for Group 1 at 28 months
remind of the results found in the earlier twin experi-
ment in Iceland and may mean protection, although our
methods did not directly prove it. Therefore we prefer to
call our findings in this field trial a delay of infection in
the vaccinees which responded to the vaccination.
Methods to detect infection in vaccinees and their
unvaccinated controls
Those who are familiar with the diagnostic work on the
HIV lentivirus infection in humans know, that positive
ELISA test is not a reliable diagnostic test for HIV infec-
tion and must be confirmed by a more reliable test, e.g.
Western Blot (WB) test on the ELISA positive serum. In
most of these cases the ELISA test is false positive. On
these grounds we selected another and more reliable test
for this field trial.
In the HIV laboratory of the Department of Microbiol-
ogy, University of Iceland, we developed Western Blot
technique for Maedi-Visna and compared it with the CF
test we had previously developed and used extensively
during the eradication of the disease from Iceland [7,8].
The comparison with the WB test showed that the CF
test became positive at the same time as the WB in all
cases tested [8]. Therefore, the CF test, simple and reli-
able in diagnostic work on many human virus diseases
became the test for natural infection in this field trial in-
stead of the cumbersome Western Blot technique. If you
compare the vaccinees with their unvaccinated controls
as shown in Groups 1 and 2 in Table 2, you see that
both the unvaccinated control twins and the vaccinated
twins that did not respond to the vaccination became
positive in the CF test at the same period of time. If you
look at Group 1 only, you see that it is during the 2nd
year of the experiment that they develop antibodies if
they are infected from the outside environment, but
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Table 2. If you look at Group 1 in Table 2 early in the
3rd year of the experiment you see that only 2 unvaccin-
ated sheep in the control group are seronegative, but 9
of their vaccinated siblings are still seronegative 2 years
after their vaccination program ended.
Boosters of vaccine
In this experiment no “boosters” of vaccine were given
to vaccinees after 3 months of age. Infections of lambs
in Group 3 are apparently not milk born infections, al-
though their mothers were seropositive both in AGID
and WB tests. This is in contrast to the experience
among unvaccinated twins born by seroconverting
mothers in Group 2. The lambs in Group 3 might have
benefited from vaccination after 6 months of age, when
passive maternal antibodies should no longer be interfer-
ing with the vaccination. Boosters late in the first year
might also have prolonged the period of delay in those
vaccineees in Groups 1 and 2, which responded to the
vaccination. Unsuccessful vaccination in Group 3 is
most likely caused by interference of passive maternal
antibodies with vaccine given so early in life, a common
finding if children are vaccinated during their first
months of life.
Clinical maedi-visna disease
The infected sheep flock, in which this experiment was
conducted, was heavily contaminated with Maedi-Visna
virus as judged by the tests on the mothers of the vacci-
nees and the rate and time of infection of the unvaccin-
ated twins in Groups 1 and 2. Yet, there was no clinical
illness in this flock and the sheep thrived well, although
they were infected. Clinical Maedi-Visna is very rare in
Cyprus, although the flocks are infected. The Icelandic
experience from the importation of Maedi-Visna in 1933
until its total eradication in 1965, was different. There,
clinical Maedi-Visna was disastrous in good sheep farm-
ing areas, culminating in the eradication by slaughter of
all the infected flocks [3].
Strain difference
The virus strains isolated from infected sheep in the
flock housing this experiment were very slowly growing
and it took many passages in tissue culture to obtain
working titers of these strains. In spite of the obvious
strain difference between the circulating virus strains
isolated from the flock and the old Icelandic vaccine
strain K796 (Table 1), monovalent vaccine made by in-
activation of whole virus K796 apparently delayed infec-
tion in more than half of the number of vaccinees in
Groups 1 and 2, when compared with their unvaccinated
siblings living in the same infected environment and
suckling the same mothers.Vaccine preparation and methods of challenge
More than twenty years ago two groups of workers, a
multinational Scandinavian group and an American
group, reported unsuccessful attempts at vaccinating
sheep with inactivated Maedi-Visna and ovine progres-
sive pneumonia (OPP) vaccines [10-13]. Both groups
used methods very different from those used in the work
described here. They used different vaccine strains of
virus, different methods of virus inactivation and con-
centration, different adjuvants, if they were used, and
last but not least different methods to challenge their
results. Both groups used high-titer live virus to test the
results of their vaccination. The Scandinavian group
gave to their vaccinees and controls live virus by the re-
spiratory route, but the American group injected large
amounts of high-titer, live virus intravenously. Neither
group had found neutralizing antibodies in their vacci-
nees, in contrast with the previous Icelandic experience
with this vaccine [4]. The question arises as to whether
it will ever be possible to determine if a lentivirus vac-
cine is working, by inoculating high titer of live virus
directly in to the circulation of the vaccinee, where sus-
ceptible living cells, such as macrophages or T-cells, are
located and may become infected. Such cells may carry
the virus to distant organs, such as lymph nodes and
lungs, where it can further multiply. Those who work
with lentiviruses need to develop more natural challenge
methods, although it takes time. Therefore, it needs to
be remembered that a challenge by injecting a high titer
of live virus is not comparable with the natural routes in
an infected sheep flock.
Inactivation
Through 19 years of work with this vaccine, all attempts
to grow virus from concentrates of vaccine following in-
activation of virus in tissue culture fluid have turned out
negative. This may be relevant to those who have pro-
blems with other lentivirus vaccines and are against the
idea of using whole inactivated virus in their experi-
ments. It is, apparently, possible to treat a lentivirus by
those conventional methods, that are used to produce
good inactivated vaccines against poliovirus, hepatitis-A
virus and influenza virus.
Conclusion
The results of vaccination in Groups 1 and 2 seem to in-
dicate that natural Maedi-Visna infection in a contami-
nated environment can be delayed, and in some cases
possibly prevented, by conventional vaccination with
formalin-inactivated whole virus vaccine adjuvanted with
aluminium hydroxide.
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